PMCB (STOCKS)
PharmaCyte Biotech, Inc. Common Stock
$0.687900
+0.034800 (+5.33%)
Prev close: $0.653100
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Joshua Nathaniel Silverman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7.36M
- Employees
- 2
- P/E (TTM)
- -0.66
- P/B (TTM)
- 0.19
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.09 | $0.00 | +0.0000 | +0.00% |
|
Sep 2025 (Q3)
|
$-0.10 | $0.00 | +0.0000 | +0.00% |
|
Jun 2025 (Q2)
|
$-0.29 | $0.00 | +0.0000 | +0.00% |
|
Mar 2025 (Q1)
|
$0.14 | $0.00 | +0.0000 | +0.00% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$2.85M |
| Operating Expenses | $4.23M |
| Research and Development | $481.17K |
| Other Operating Expenses | $3.75M |
| Operating Income/Loss | -$4.23M |
| Income/Loss From Continuing Operations After Tax | -$10.12M |
| Income/Loss From Continuing Operations Before Tax | -$10.12M |
| Net Income/Loss | -$10.12M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$3.05M |
| Net Income/Loss Attributable To Parent | -$7.07M |
| Net Income/Loss Available To Common Stockholders, Basic | -$11.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $6.40M |
| Preferred Stock Dividends And Other Adjustments | $3.97M |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic | -$7.63M |
| Basic Earnings Per Share | -$1.39 |
| Diluted Earnings Per Share | -$1.39 |
| Basic Average Shares | 13,597,576 |
| Diluted Average Shares | 20,393,355 |
| Assets | $55.98M |
| Current Assets | $23.02M |
| Noncurrent Assets | $32.95M |
| Intangible Assets | $1.55M |
| Other Non-current Assets | $31.40M |
| Liabilities | $19.42M |
| Current Liabilities | $1.58M |
| Accounts Payable | $1.02M |
| Other Current Liabilities | $556.05K |
| Noncurrent Liabilities | $17.85M |
| Equity | $35.24M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $35.24M |
| Liabilities And Equity | $55.98M |
| Net Cash Flow From Operating Activities | -$4.52M |
| Net Cash Flow From Operating Activities, Continuing | -$4.52M |
| Net Cash Flow From Investing Activities | -$3.00M |
| Net Cash Flow From Investing Activities, Continuing | -$3.00M |
| Net Cash Flow From Financing Activities | $2.09M |
| Net Cash Flow From Financing Activities, Continuing | $2.09M |
| Exchange Gains/Losses | -$860.00 |
| Net Cash Flow | -$5.43M |
| Net Cash Flow, Continuing | -$5.43M |
| Comprehensive Income/Loss | -$7.07M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$7.07M |
| Other Comprehensive Income/Loss | -$860.00 |